At a glance
ClinicalIndex Comparison RecordN/AUnknown· 21 enrolled
Drug / intervention
RheOxdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Feasibility Study: A Safety Evaluation of RheOx on Patients With Chronic Bronchitis in the United States
In Brief
A clinical study evaluating RheOx for Chronic Bronchitis and Copd Bronchitis. Targeting 21 participants across 8 sites.
Detailed Summary
An early feasibility study (EFS) to assess the safety and clinical utility of RheOx on patients with chronic bronchitis in the United States.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Bronchitis, Copd Bronchitis
CountriesUnited States
Collaborators--
Timeline
N/AUnknownOverdue
20192020202120222023202420252026
Enrollment StartJul 2018
First PostedAug 2018
Primary CompletionJan 2021
Study CompletionDec 2024
TodayJul 2026
First PostedAug 15, 2018
Enrollment StartJul 6, 2018
Primary CompletionJan 30, 2021
Study CompletionDec 30, 2024
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 7.9 years ago
Interventions
RheOxdevice
RheOx is a device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.